X

Drug Profile

Research programme: peptide therapeutics - Altus Pharmaceuticals

Alternative Names: ALTU-141; ALTU-242; ALTU-244

Latest Information Update: 16 Sep 2016

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Altus Pharmaceuticals
Class Enzymes
Mechanism of Action Enzyme inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Gout; Inflammatory bowel diseases; Neonatal jaundice

Most Recent Events

16 Sep 2016 Discontinued - Preclinical for Gout in USA (PO) (Altus pipeline; September 2016)
15 Jun 2009 Suspended - Preclinical for Gout in USA (PO)
15 Mar 2007 ALTU 242 is still in active development

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com